Last updated: 11/04/2018 02:53:13
Dose-Escalating Study Of SB-485232 Administered Intravenously Every 28 Days To Adults With Solid Tumors Or Lymphomas
GSK study ID
485232/003
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Phase I, Dose-Escalation Study to Assess the Safety and Pharmacokinetics of SB- 485232 Administered as Five Daily Intravenous Infusions Repeated Every 28 Days in Adult Patients with Solid Tumors and Lymphomas
Trial description: SB-485232 will be administered as five daily intravenous (IV) infusions repeated every 28 days in adult subjects with advanced solid tumors or lymphomas. Subjects may receive up to 6 cycles of treatment unless progressive disease or unacceptable toxicity is noted. Three dose levels of drug will be investigated. Safety evaluations, including blood sampling for various laboratory tests, will be conducted. Additional blood samples will also be taken to measure the amount of drug in the body at specific times.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
Evaluation of adverse events and changes in laboratory values. The potential dose is a dose regimen with no more than 2 out of 6 patients experiencing a dose-limiting toxicity.
Timeframe: 6 Months
Secondary outcomes:
Evaluation for the presence of anti-SB-485232 antibodies, IL-18 neutralizing activity, and clinical sequelae. Pharmacokinetic endpoints are AUC, Cmax, Cmin, CL,Vss, and t1/2. Flow cytometry data. Assessments of disease.
Timeframe: 6 Months
Interventions:
Enrollment:
12
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Solid Tumor Cancer, Lymphoma
Product
iboctadekin
Collaborators
Not applicable
Study date(s)
April 2004 to April 2006
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
no
- Inclusion criteria:
- Histopathological confirmation of cancer limited to a solid tumor malignancy or follicular lymphoma.
Inclusion and exclusion criteria
Inclusion criteria:
- Inclusion criteria:
- Histopathological confirmation of cancer limited to a solid tumor malignancy or follicular lymphoma.
- Advanced or metastatic disease.
- Measurable disease.
- Females of child-bearing potential must use adequate birth control.
- Karnofsky Performance Status of 70% or greater.
- Predicted life expectancy of at least 12 weeks in the estimation of the physician conducting the study (Principal Investigator).
- Adequate laboratory results.
- Subjects with history of coronary artery disease must have a stress test without clinically significant abnormalities.
- Subjects with a history of congestive heart failure, myocardial infarction or prior anthracycline chemotherapy, must have a MUGA (Multiple Gated Acquisition) scan which demonstrates a left ventricular ejection fraction equal to or greater than 40%.
- Signed informed consent form Exclusion Criteria:
- Female subject is pregnant or nursing (lactating).
- Active, chronic or uncontrolled infections requiring systemic antibiotic therapy.
- Serious medical or psychiatric disorder that would interfere with the subject''s safety or ability to sign the informed consent.
- Leptomeningeal disease or evidence of prior or current metastatic brain disease.
- Receiving concurrent chemotherapy, immunotherapy, radiotherapy, corticosteroid therapy, or investigational therapy.
- Received chemotherapy, radiotherapy, immunotherapy, hormonal therapy or biological therapy for cancer or underwent a surgical procedure (except for minor surgical procedures) within 4 weeks before beginning treatment with SB-485232 (6 weeks in case of nitrosureas or mitomycin C).
- Exposed to an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of SB-485232.
- Severe concurrent disease or condition, including clinically significant autoimmune disease, which in the judgement of the physician conducting the study (the principal investigator) would render the patient inappropriate for study participation.
- History of ventricular arrhythmias requiring drug or device therapy.
- An unresolved or unstable, serious toxicity from prior administration of another investigational product.
- Psychological, familial, sociological, or geographical limitations that do not permit compliance with this protocol.
- Received prior SB-485232 therapy.
- Poor venous access.
Trial location(s)
Location
GSK Investigational Site
Pittsburgh, Pennsylvania, United States, 15213-2584
Status
Study Complete
Location
GSK Investigational Site
Boston, Massachusetts, United States, 02215
Status
Study Complete
Location
GSK Investigational Site
Indianapolis, Indiana, United States, 46202
Status
Study Complete
Study documents
No study documents available.
Results overview
Study Results yet to be posted
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
2006-04-04
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website